US nod for Akcea/Ionis’ Tegsedi
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Oct 8, 2018 | News | 0
Akcea and Ionis’ Tegsedi has won US approval for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Aug 28, 2018 | News | 0
US regulators have rejected Akcea/Ionis’ application to market Waylivra for the ultra-rare rare lipid disorder familial chylomicronemia syndrome (FCS).
Read Moreby Selina McKee | Jul 17, 2018 | News | 0
European regulators have approved Akcea and Ionis’ Tegsedi for patients with hereditary transthyretin amyloidosis (hATTR), a rare disease causing build up of amyloid in the peripheral nervous system and multiple organs.
Read Moreby Selina McKee | Apr 10, 2018 | News | 0
AstraZeneca has bought rights to an experimental antisense therapy from Ionis Pharmaceuticals, in a deal that could be worth more than $300 million
Read Moreby Selina McKee | Aug 14, 2017 | News | 0
GlaxoSmithkline has turned down options to take on board Ionis Pharmaceuticals’ experimental antisense therapies inotersen and IONIS-FB-LRx following a pipeline revamp.
Read Moreby Dominic Tyer | May 19, 2017 | News | 0
Meets its Phase III targets but concerns remain over its side effects profile
Read Moreby Selina McKee | Jan 6, 2017 | News | 0
Novartis has signed an exclusive option agreement with Ionis and affiliate Akcea to license two investigational therapies that could significantly reduce cardiovascular risk in patients living with elevated levels of lipoproteins Lp(a) and ApoCIII.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
